1
|
Zaucha JM, Malkowski B, Chauvie S, Subocz E, Tajer J, Kulikowski W, Fijolek-Warszewska A, Biggi A, Fallanca F, Kobylecka M, Dziuk M, Woszczyk D, Rybka J, Kroll-Balcerzak R, Bergesio F, Romanowicz A, Chamier-Cieminska A, Kurczab P, Giza A, Lesniewski-Kmak K, Zaucha R, Swietlik D, Wróbel T, Knopinska-Posluszny W, Walewski J, Gallamini A. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study. Ann Oncol 2018; 28:3051-3057. [PMID: 28950332 DOI: 10.1093/annonc/mdx524] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Interim PET after two ABVD cycles (iPET2) predicts treatment outcome in classical Hodgkin's lymphoma. To test whether an earlier assessment of chemosensitivity would improve the prediction accuracy, we launched a prospective, multicenter observational study aimed at assessing the predictive value of iPET after one ABVD (iPET1) and the kinetics of response assessed by sequential PET scanning. Patients and methods Consecutive patients with newly diagnosed classical Hodgkin's lymphoma underwent interim PET scan after one ABVD course (iPET1). PETs were interpreted according to the Deauville score (DS) as negative (-) (DS 1-3) and positive (+) (DS 4, 5). Patients with iPET1 DS 3-5 underwent iPET2. Results About 106 early (I-IIA) and 204 advanced (IIB-IV) patients were enrolled between January 2008 and October 2014. iPET1 was (-) in 87/106 (82%) or (+) in 19/106 (18%) of early, and (-) in 133/204 (65%) or (+) in 71/204 (35%) of advanced stage patients, respectively. Twenty-four patients were excluded from response analysis due to treatment escalation. After a median follow-up of 38.2 (3.2-90.2) months, 9/102 (9%) early and 43/184 (23%) advanced patients experienced a progression-free survival event. At 36 months, negative and positive predictive value for iPET1 were 94% and 41% (early) and 84% and 43% (advanced), respectively. The kinetics of PET response was assessed in 198 patients with both iPETs. All 116 patients with iPET1(-) remained iPET2(-) (fast responders), 41/82 with IPET1(+) became iPET2(-) (slow responders), and the remaining 41 stayed iPET2(+) (non-responders); progression-free survival at 36 months for fast, slow and non-responders was 0.88, 0.79 and 0.34, respectively. Conclusion The optimal tool to predict ABVD outcome in HL remains iPET2 because it distinguishes responders, whatever their time to response, from non-responders. However, iPET1 identified fast responders with the best outcome and might guide early treatment de-escalation in both early and advanced-stage HL.
Collapse
Affiliation(s)
- J M Zaucha
- Gdynia Oncology Center, Gdynia.,Departments of Oncological Propedeutics.,Hematology and Transplantology, Medical University of Gdańsk, Gdańsk
| | - B Malkowski
- Nuclear Medicine Department, Oncology Center, Bydgoszcz.,Positron Emission Tomography and Molecular Imagining Department, Collegium Medicum N. Copernicus University, Bydgoszcz, Poland
| | - S Chauvie
- Medical Physics Department, Santa Croce e Carle Hospital, Cuneo, Italy
| | - E Subocz
- Department of Hematology, Military Institute of Medicine, Warszawa
| | - J Tajer
- Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Institute, Warszawa
| | - W Kulikowski
- Clinical Department of Hematology, Interior Ministry Hospital, Warmia.,Mazury Medical University, Olsztyn
| | | | - A Biggi
- Nuclear Medicine Department, Santa Croce e Carle Hospital, Cuneo
| | - F Fallanca
- Nuclear Medicine Department, San Raffaele Hospital, Milano, Italy
| | - M Kobylecka
- Nuclear Medicine Department, Warsaw Medical University, Warszawa
| | - M Dziuk
- Nuclear Medicine Department, Military Institute of Medicine, Warszawa
| | - D Woszczyk
- Hematology Unit, Regional Hospital, Opole
| | - J Rybka
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw
| | | | - F Bergesio
- Medical Physics Department, Santa Croce e Carle Hospital, Cuneo, Italy
| | - A Romanowicz
- Department of Hematology, Central Clinical Hospital MSW, Warszawa
| | | | - P Kurczab
- Poradnia Onkologiczna z Oddzialem Chemioterapii Dziennej NZOZ Mrukmed, Rzeszów
| | - A Giza
- Department of Hematology, Jagiellonian University Medical College, Krakow
| | - K Lesniewski-Kmak
- Gdynia Oncology Center, Gdynia.,Departments of Oncological Propedeutics.,Hematology and Transplantology, Medical University of Gdańsk, Gdańsk
| | - R Zaucha
- Department of Clinical Oncology and Radiotherapy
| | - D Swietlik
- Intrafaculty College of Medical Informatics & Biostatistics, Medical University of Gdansk, Poland
| | - T Wróbel
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw
| | - W Knopinska-Posluszny
- Clinical Department of Hematology, Interior Ministry Hospital, Warmia.,Mazury Medical University, Olsztyn
| | - J Walewski
- Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Institute, Warszawa
| | - A Gallamini
- Department of Research, Innovation and Statistics, A. Lacassagne Cancer Center, Nice, France
| |
Collapse
|
2
|
Rutkowski J, Ślebioda T, Zaucha R. Elevated fraction of CTLA-4(+) and PD-1(+) T cells in peripheral blood with stimulation of Th1, Th2 and Th17 type immune response after stereotactic radiotherapy for early lung cancer – a prospective study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw381.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Zietarska M, Krawczyk J, Wernio E, Zaucha R, Matgorzewicz S. SUN-P147: Nutritional Status Assessment in Colorectal Cancer Patients Qualified to Chemotherapy. Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30490-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
4
|
Rutkowski J, Zaucha R, Slebioda T. PD-0424: Immune response profile assessment after stereotactic radiotherapy for lung cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40420-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer 2013; 49:3616-24. [PMID: 23899532 DOI: 10.1016/j.ejca.2013.07.003] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Accepted: 07/01/2013] [Indexed: 12/16/2022]
Abstract
BACKGROUND The aim of developing oral fluorouracil (5-FU) is to provide a more convenient administration route with similar efficacy and the best achievable tolerance. S-1, a novel oral fluoropyrimidine, was specifically designed to overcome the limitations of intravenous fluoropyrimidine therapies. PATIENTS AND METHODS A multicentre, randomised phase 3 trial was undertaken to compare S-1/cisplatin (CS) with infusional 5-FU/cisplatin (CF) in 1053 patients with untreated, advanced gastric/gastroesophageal adenocarcinoma. This report discusses a post-hoc noninferiority overall survival (OS) and safety analyses. RESULTS Results (1029 treated; CS = 521/CF = 508) revealed OS in CS (8.6 months) was statistically noninferior to CF (7.9 months) [hazard ratio (HR) = 0.92 (two-sided 95% confidence interval (CI), 0.80-1.05)] for any margin equal to or greater than 1.05. Statistically significant safety advantages for the CS arm were observed [G3/4 neutropenia (CS, 18.6%; CF, 40.0%), febrile neutropenia (CS, 1.7%; CF, 6.9%), G3/4 stomatitis (CS, 1.3%; CF, 13.6%), diarrhoea (all grades: CS, 29.2%; CF, 38.4%) and renal adverse events (all grades: CS, 18.8%; CF, 33.5%)]. Hand-foot syndrome, infrequently reported, was mainly grade 1/2 in both arms. Treatment-related deaths were significantly lower in the CS arm than the CF arm (2.5% and 4.9%, respectively; P<0.047). CONCLUSION CS is noninferior to CF with a better safety profile and provides a new treatment option for patients with advanced gastric carcinoma.
Collapse
Affiliation(s)
- J A Ajani
- Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Weber D, Miller R, Villa S, Kadish S, Anacak Y, Abusaris H, Ozygit G, Baumert B, Zaucha R, Pica A. The Results of Surgery, with or without Radiotherapy, for Primary Spinal Myxopapillary Ependymoma: A Retrospective Study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2008. [DOI: 10.1016/j.ijrobp.2008.06.1526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Zaucha R, Holmberg L, Maloney D, Press O, Bensinger W. BEAM vs BuMelTT high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell infusion (HSCT) in the treatment of non-Hodgkin’s lymphoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Zaucha
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - L. Holmberg
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - D. Maloney
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - O. Press
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| | - W. Bensinger
- Medcl Univ of Gdansk, Gdansk, Poland; Fred Hutchinson Cancer Research Ctr, Seattle, WA
| |
Collapse
|
8
|
Zaucha R, Sosińska-Mielcarek K, Jassem J. Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. Breast 2004; 13:321-4. [PMID: 15325667 DOI: 10.1016/j.breast.2004.05.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2004] [Revised: 04/14/2004] [Accepted: 05/18/2004] [Indexed: 11/18/2022] Open
Abstract
The prognosis of breast cancer patients with liver metastases is extremely poor. Here we present the case of a 66-year-old female breast cancer patient with multiple liver metastases diagnosed 2 years after a radical modified mastectomy followed by adjuvant tamoxifen. At progression, anthracycline-based chemotherapy was administered, but a CT scan following two cycles of FEC (5-fluorouracil, epirubicin, cyclophosphamide) showed progression of the liver metastases. Chemotherapy was therefore switched to medroxyprogesterone acetate (MPA). After 3 months the patient's general status improved, and disease stabilization was observed at the next CT scan. A further 4 months of MPA treatment resulted in complete response of all liver lesions. Treatment with oral MPA was continued for 4 years. At present, 11 years after the diagnosis of metastatic liver involvement, the patient is alive, free of cancer, and fully ambulatory. Despite bulky visceral disease and chemoresistance, hormonal treatment with MPA resulted in a spectacular and long-lasting response.
Collapse
Affiliation(s)
- R Zaucha
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, ul. Debinki 7, 80-211 Gdansk, Poland.
| | | | | |
Collapse
|
9
|
Bednaruk-Młyński E, Zaucha R, Kobierska A, Jassem J. 9/Radykalna radioterapia chorych na raka pęcherza moczowego w stopniu T2–T4. Rep Pract Oncol Radiother 2004. [DOI: 10.1016/s1507-1367(04)70865-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
10
|
Zaucha R, Sosińska-Mielcarek K, Zander I, Jassem J. 296. Spinal cord ependymoma: A Retrospective study of 12 patients. Rep Pract Oncol Radiother 2003. [DOI: 10.1016/s1507-1367(03)70779-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
11
|
Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, Martin PJ, Flowers ME, Storek J, Georges G, Storb R, Torok-Storb B. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98:3221-7. [PMID: 11719357 DOI: 10.1182/blood.v98.12.3221] [Citation(s) in RCA: 197] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
A retrospective analysis of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cell (G-PBMC) products harvested from healthy donors indicates significant variability in both the absolute number and relative proportion of CD34, CD3, and CD14 cells obtained. This report examined whether variations in the cellular composition of G-PBMC products correlated with clinical outcomes after myeloablative allogeneic transplantation. The numbers of CD34, CD3, and CD14 cells infused into 181 human leukocyte antigen (HLA)-identical sibling recipients were analyzed with respect to tempo of engraftment, acute graft-versus-host-disease (GVHD), clinical extensive chronic GVHD, overall survival, and disease relapse. Neither acute GVHD, overall survival, nor disease relapse was statistically significantly associated with CD34, CD3, or CD14 cell doses or the CD14 to CD3 ratio. CD3 and CD14 cell doses and CD14 to CD3 ratios did not correlate with the tempo of neutrophil and platelet engraftment. However, increasing CD34 cell numbers were significantly associated with accelerated neutrophil (P =.03) and platelet (P =.01) engraftment. Higher doses of CD34 cells (> 8.0 x 10(6)/kg) were also associated with a significantly increased hazard of clinical extensive chronic GVHD (HR = 2.3, 95% confidence interval [CI] 1.4-3.7, P =.001), but neither CD3 nor CD14 doses were statistically significantly associated with chronic GVHD. It was concluded that CD34 cell dose in G-PBMC grafts appears to affect both the engraftment kinetics and the development of clinical extensive chronic GVHD in HLA-identical sibling recipients but without a demonstrable impact on survival, relapse, and acute GVHD. Given the morbidity associated with extensive chronic GVHD, efforts to further accelerate engraftment in HLA-matched sibling transplants by increasing CD34 cell number in G-PBMC products may be counterproductive.
Collapse
Affiliation(s)
- J M Zaucha
- Fred Hutchinson Cancer Research Center, the University of Washington, and the Veterans Affairs Medical Center, Seattle, WA 98109-1024, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Welnicka-Jaskiewicz M, Zaucha R, Wojcik-Tomaszewska J, Burski T, Kuziemski K, Jassem J. The assessment of cardiovascular injury and early and late lung complications after irradiation for breast cancer. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81170-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Zaucha R, Kobierska A, Nowaczyk M, Zaborowska J, Jassem J. 67. Radical radiotherapy of muscle-invading bladder cancer (BC): a retrospective analysis of 49 patients. Rep Pract Oncol Radiother 2001. [DOI: 10.1016/s1507-1367(01)70437-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
14
|
Zaucha R, Wełnicka-Jaśkiewicz M. [Hemangioblastoma of the breast]. Pol Arch Med Wewn 1996; 95:145-6. [PMID: 8677209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- R Zaucha
- Kliniki Onkologii i Radioterapii AM w Gdańsku
| | | |
Collapse
|
15
|
Krześniak-Bohdan M, Bobek-Billewicz B, Zaucha R. [Diagnostic difficulties in the case of a brain tumor of embryonic origin in an 18-year old man]. Pol Tyg Lek 1995; 50:82-4. [PMID: 8650043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
A case of an 18-year-old man with symptoms of diabetes insipidus and signs of hypothalamus injury was presented. The computerized tomography of the head and the examination of the cerebrospinal fluid suggested an inflammatory process. After a few-month observation, due to the increased level of tumor markers (human chorionic gonadotropin-HCG) and the results of the MR imaging, a tumor of an embryonic origin was recognized. The type of the tumor is unknown because a biopsy specimen for the histopathology could not have been taken.
Collapse
|
16
|
Zaucha R, Zander I, Mechlińska-Baczkowska J. [Pigmented villonodular synovitis of the hip. Case report]. Pol Tyg Lek 1993; 48:653-4. [PMID: 7808942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A 35-year woman suffering from the tumor of the right groin for 5 years was diagnosed as a diffuse pigmented villonodular synovitis and tenosynovitis following a 7-month follow-up and examinations. Patient was treated with irradiation which produced a subjective improvement but no significant objective response to the treatment was noted.
Collapse
Affiliation(s)
- R Zaucha
- Kliniki Radioterapii AM, Gdańsku
| | | | | |
Collapse
|